oral anticoagulant

口服抗凝剂
  • 文章类型: Case Reports
    肝素是一种抗凝剂,已广泛用于各种临床环境,从血栓预防到血栓栓塞的治疗。肝素诱导的血小板减少症(HIT)是一种罕见的医学疾病,如果无法识别,则会出现严重的并发症,它具有共病和死亡的重大风险。HIT的发生率在低分子量肝素中相对较不常见。HIT在静脉系统比动脉循环系统更常见,很少看到由于HIT引起的多血管冠状动脉血栓形成。我们特此报告一例继发于低分子量HIT的多血管冠状动脉血栓形成,以ST段抬高型心肌梗死为例。我们从该病例中了解到,低分子量肝素可引起继发于HIT的血栓形成,HIT可能是ST段抬高心肌梗死和最近暴露于低分子量肝素的患者的鉴别诊断之一。
    Heparin is an anticoagulant which has been widely used in various clinical settings, from thromboprophylaxis to the treatment of thromboembolism. Heparin-induced thrombocytopenia (HIT) is a rare medical condition with severe complications if unrecognised, and it carries significant risks of co-morbidities and mortality. The incidence of HIT is relatively less common in low molecular weight heparin. HIT is more common in the venous system than the arterial circulatory system, and it is rare to see multi-vessel coronary artery thrombosis due to HIT. We hereby report a case of multi-vessel coronary thrombosis secondary to low molecular weight HIT, presenting as a case of ST-segment elevation myocardial infarction. We learned from the case that low molecular weight heparin can cause thrombosis secondary to HIT and HIT could be one of the differential diagnoses in those presenting with ST-elevation myocardial infarct and recent exposure to low molecular weight heparin.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    UNASSIGNED:左心室血栓(LVT)是糖尿病患者心肌梗死(MI)的公认并发症。由LVT引起的栓塞并发症是关键的临床问题,并且与长期生存率恶化有关。
    UNASSIGNED:一名45岁的男子因持续左腹痛1周且左腿疲劳而被送往急诊科。腹痛的原因是肾动脉栓塞,脾动脉,和心源性血栓形成引起的肠系膜上动脉,进一步导致脾梗死和肾梗死。尚不清楚何时发生MI,因为患者没有典型的严重胸痛,这可能与糖尿病并发症有关,如糖尿病周围神经病变。糖尿病在MI和LVT形成中起关键作用。因为冠状动脉造影提示三血管疾病,进行经皮冠状动脉腔内成形术(PTCA),在左冠状动脉前降支(LAD)内置入两个药物洗脱支架。由于缺乏随机对照临床试验,LVT和相关栓塞的治疗一直存在争议。根据目前的指导方针,该患者接受低分子肝素和华法林(口服抗凝药)治疗3个月,同时接受阿司匹林(100mg/日)和氯吡格雷(75mg/日)治疗1年.无严重出血并发症,随访检查显示左心室无血栓或进一步的外周血栓事件.
    UNASSIGNED:由MI引起的LVT周围栓塞导致多器官栓塞仍然很少发生。糖尿病在MI和LVT形成中起关键作用。成功的梗死相关冠状动脉血运重建和抗凝治疗对于最大程度地减少心肌损伤和预防LVT很重要。本病例将帮助临床医生识别和管理糖尿病患者的LVT和相关的外周动脉血栓事件与抗凝治疗。
    UNASSIGNED: Left ventricular thrombus (LVT) is a well-recognized complication of myocardial infarction (MI) in patients with diabetes. An embolic complication caused by LVT is a key clinical problem and is associated with worsened long-term survival.
    UNASSIGNED: A 45-year-old man with persistent left abdominal pain for 1 week and left leg fatigue was admitted to the emergency department. The cause of abdominal pain was embolism of the renal artery, the splenic artery, and the superior mesenteric artery caused by cardiogenic thrombosis, which further led to splenic infarction and renal infarction. It was unclear when MI occurred because the patient had no typical critical chest pain, which may have been related to diabetic complications, such as diabetic peripheral neuropathy. Diabetes plays a pivotal role in MI and LVT formation. Because coronary angiography suggested triple vessel disease, percutaneous transluminal coronary angioplasty (PTCA) was conducted, and two drug-eluting stents were placed in the left anterior descending coronary artery (LAD). Due to a lack of randomized clinical control trials, the therapy of LVT and associated embolization has been actively debated. According to the present guidelines, this patient was treated with low-molecular-weight heparin and warfarin (oral anticoagulants) for 3 months in addition to aspirin (100 mg/day) and clopidogrel (75 mg/day) for 1 year. No serious bleeding complications were noted, and a follow-up examination showed no thrombus in the left ventricle or further peripheral thrombotic events.
    UNASSIGNED: Peripheral embolization of LVT caused by MI leading to multiple organ embolization remains a rare occurrence. Diabetes plays a pivotal role in MI and LVT formation. Successful revascularization of the infarct-related coronary artery and anticoagulation therapy is important to minimize myocardial damage and prevent LVT. The present case will help clinicians recognize and manage LVT in patients with diabetes and related peripheral arterial thrombotic events with anticoagulation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: English Abstract
    口服抗凝剂可能有严重的不良事件风险,特别是当它被启动时,修改或中断。通过药物和解进行药学服务可以提高这些药物的获益风险比。一项前瞻性和介入性单中心研究于2018年3月至8月在医学和外科单位进行。包括处方口服抗凝剂并来自门诊的患者。这些患者在入院和出院时接受了药物和解。研究了差异的频率和类型。使用Cornish等人评估了它们的重力等级。规模。这项研究包括162名患者。入院时的药物和解允许检测到133个无意的差异,其中16个对患者来说是高风险的,其中包括9个关于口服抗凝剂处方的错误。关于出院时的和解,已检测到51个无意的差异:其中12个代表患者的高风险,包括8个关于口服抗凝剂处方的错误。差异的接受率为86%,反映了差异的严重程度。如果我们考虑到具有严重临床影响的差异,则该结果达到96.4%。这项研究强调了口服抗凝剂代表了长期实施药学服务的相关优先标准。这确保了患者从入院到出院的管理。我们方法的最后一步是研究向社区护理人员传输数据的需求。
    Oral anticoagulant can have a significant risk of adverse events, particularly when it is initiated, modified or interrupted. Pharmaceutical care through medication reconciliation could improve the benefit-to-risk ratio of these drugs. A prospective and interventional single center study was conducted from March through August 2018 in medicine and surgical units. Patients with an oral anticoagulant prescribed and coming from outpatient sector were included. These patients received a medication reconciliation at admission and discharge. Frequency and type of discrepancies were studied. Their gravity rating was assessed using the Cornish et al. scale. This study included 162 patients. The medication reconciliation at the admission allowed the detection of 133 unintentional discrepancies which 16 of them represented a high risk for the patient included nine errors about oral anticoagulant prescribing. Concerning the reconciliation at discharge, 51 unintentional discrepancies had been detected: 12 of them represented a high risk for the patient included eight errors about oral anticoagulant prescription. The acceptance rate of the discrepancies was 86% and reflected discrepancies severity. This result reached 96.4% if we took into account discrepancies with a severe clinical impact. This study highlighted oral anticoagulant represented relevant prioritization criteria to the long-lasting implementation of pharmaceutical care. This secures the management of the patient since the admission until the hospital discharge. The last step of our approach would be to study the needs about data transmission to the community caregivers.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    UNASSIGNED: Direct oral anticoagulants (DOAC) are an attractive alternative over vitamin K antagonists. They have several advantages in primary and secondary prevention of thromboembolisms due to atrial fibrillation, as well as in prevention and treatment of thromboembolic venous disease. They have fast onset action, do not need laboratory controls in patients with normal renal function, and they have practically no interference with the patient\'s diet or medications. The strongest objection to their use was the lack of reversal agents that could be used in case of life-threatening haemorrhage or the need for emergency surgery. Dabigatran was the first DOAC to have its own specific reversal agent: idarucizumab, a monoclonal antibody.
    UNASSIGNED: We report here the case of a patient undergoing treatment with dabigatran that suffered an expansive subdural haematoma secondary to a cranial injury. The condition was life-threatening and required emergency surgery. Anticoagulation was successfully reversed with idarucizumab.
    UNASSIGNED: Emergency surgery in patients in treatment with DOAC is associated with an increased risk of bleeding. With the use of a specific antidote to block the action of the anticoagulant, as in the case of idarucizumab with dabigatran, the risk of complications during and after emergency surgery is reduced. This is the first case report with which the successful use of idarucizumab in Latin America is documented.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Letter
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号